Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Bloemendal HJ"" wg kryterium: Autor


Tytuł :
The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
Autorzy :
Schuurhuizen CSEW
Verheul HMW
Braamse AMJ
Buffart LM
Bloemendal HJ
Dekker J
Konings IRHM
Pokaż więcej
Temat :
Cumulative toxicity
treatment-related toxicity
adverse events
quality of life
metastatic colorectal cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
Cancer Management and Research, Vol Volume 10, Pp 3015-3021 (2018)
Opis pliku :
electronic resource
Relacje :
https://www.dovepress.com/the-predictive-value-of-cumulative-toxicity-for-quality-of-life-in-pat-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322
Dostęp URL :
https://doaj.org/article/236c04f7327742628294fe7b41eaf425
Czasopismo naukowe
Tytuł :
Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study
Autorzy :
May, AM
Bosch, MJ
Velthuis, MJ
Van der Wall, E
Steins Bisschop, CN
Los, M
Erdkamp, F
Bloemendal, HJ
De Roos, MA
Verhaar, M
Ten Bokkel Huinink, D
Peeters, PH
De Wit, GA
Pokaż więcej
Temat :
colon cancer
breast cancer
Rehabilitation Medicine
Research
coste-effectiveness
health care economics and organizations
exercise intervention
adjuvant treatment
quality of life
Źródło :
BMJ Open. 7
Tytuł :
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.
Autorzy :
Ooft SN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Schipper L; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
McLean CM; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Prevoo W; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hoes LR; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
Chalabi M; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van der Velden D; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center AMC, Amsterdam, The Netherlands.
van Leerdam M; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Boot H; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Grootscholten C; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands.
Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
Cuppen E; Oncode Institute, Utrecht, The Netherlands; Division of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100103. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Autorzy :
Slootbeek PHJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Duizer ML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
van der Doelen MJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Kloots ISH; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Kuppen MCP; Institute for Medical Technology Assessment (iMTA), Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
Uyl-de Groot CA; Institute for Medical Technology Assessment (iMTA), Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Pamidimarri Naga S; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Ligtenberg MJL; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Schalken JA; Department of Experimental Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Kroeze LI; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Jan 15; Vol. 148 (2), pp. 385-395. Date of Electronic Publication: 2020 Oct 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Repair*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Prostatic Neoplasms, Castration-Resistant/*genetics
Aged ; BRCA2 Protein/genetics ; Carboplatin/administration & dosage ; DNA Damage ; Drug Resistance, Neoplasm ; Germ-Line Mutation ; Humans ; Kaplan-Meier Estimate ; Male ; Neoplasm Staging ; Netherlands/epidemiology ; Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Taxoids/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study.
Autorzy :
de Joode K; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Dumoulin DW; Department of Pulmonary Diseases, Erasmus MC, Rotterdam, the Netherlands.
Tol J; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands.
Beerepoot LV; Department of Internal Medicine, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands.
van den Berkmortel FWPJ; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands.
Mutsaers PGNJ; Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
van Diemen NGJ; Department of Internal Medicine, Bernhoven, Uden, the Netherlands.
Visser OJ; Department of Hematology, Isala Hospital, Zwolle, the Netherlands.
Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
van Laarhoven HWM; Department of Medical Oncology, Cancer Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Hendriks LEL; Department of Pulmonary Diseases GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Dingemans AC; Department of Pulmonary Diseases, Erasmus MC, Rotterdam, the Netherlands.
van der Veldt AAM; Department of Medical Oncology and Department of Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: .
Pokaż więcej
Corporate Authors :
DOCC Investigators
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Dec; Vol. 141, pp. 171-184. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
COVID-19/*epidemiology
Neoplasms/*epidemiology
Neoplasms/*virology
Aged ; Cohort Studies ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Neoplasms/therapy ; Netherlands/epidemiology ; Pandemics ; Registries ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Autorzy :
Chibaudel B; Department of Medical Oncology, Franco-British Hospital-Fondation Cognacq-Jay, Levallois-Perret, France.; Statistical Unit, Aide et Recherche en Cancérologie Digestive, Foundation, Levallois-Perret, France.
Henriques J; Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1098, Besançon, France.
Rakez M; Statistical Unit, Aide et Recherche en Cancérologie Digestive, Foundation, Levallois-Perret, France.
Brenner B; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqva, Tel Aviv University, Tel Aviv, Israel.
Kim TW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Martinez-Villacampa M; Department of Medical Oncology, Institut Català d'Oncologia-Bellvitge Institute for Biomedical Research, L'Hospitalet, Barcelona, Spain.
Gallego-Plazas J; Department of Medical Oncology, General Universitario de Elche Hospital, Elche, Spain.
Cervantes A; Department of Medical Oncology, Hospital Clinico Universitario de Valencia, Valencia, Spain.
Shim K; Department of Medical Oncology, Lakeridge Health R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, Ontario, Canada.
Jonker D; Division of Medical Oncology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.
Guerin-Meyer V; Department of Gastroenterology and Hepatology, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.
Mineur L; Department of Radiotherapy and Oncology Gastrointestinal and Liver, Institut Sainte Catherine, Avignon, France.
Banzi C; Medical Oncology Unit, Arcispedale Santa Maria Nuova-Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.
Dewdney A; Department of Oncology, Weston Park Hospital Cancer Research Centre, Sheffield, United Kingdom.
Dejthevaporn T; Medical Oncology Unit, Ramathibodi Hospital, Bangkok, Thailand.
Bloemendal HJ; Department of Internal Medicine and Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
Roth A; Digestive Tumor Unit, Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Moehler M; First Department of Internal Medicine, University Hospital of Mainz, Mainz, Germany.
Aranda E; Department of Medical Oncology, Reina Sofía University Hospital, Córdoba, Spain.
Van Cutsem E; Department of Gastroenterology and Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KULeuven, Leuven, Belgium.
Tabernero J; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Universitat de Vic-Universitat Central de Catalunya, International Oncology Bureau-Quiron, Barcelona, Spain.
Schmoll HJ; Department of Oncology and Hematology, Martin Luther University, Halle, Germany.
Hoff PM; Department of Radiology and Oncology, Instituto de Câncer do Estado de São Paulo, São Paulo, Brazil.
André T; Department of Medical Oncology, Hôpital Saint-Antoine, Assitance Publique des Hôpitaux de Paris, Paris, France.
de Gramont A; Department of Medical Oncology, Franco-British Hospital-Fondation Cognacq-Jay, Levallois-Perret, France.; Statistical Unit, Aide et Recherche en Cancérologie Digestive, Foundation, Levallois-Perret, France.
Pokaż więcej
Źródło :
JAMA network open [JAMA Netw Open] 2020 Oct 01; Vol. 3 (10), pp. e2020425. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bevacizumab/*therapeutic use
Capecitabine/*therapeutic use
Colonic Neoplasms/*drug therapy
Colonic Neoplasms/*mortality
Oxaloacetates/*therapeutic use
Aged ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds/therapeutic use ; Proportional Hazards Models ; Treatment Outcome
SCR Protocol :
Folfox protocol; XELOX
Czasopismo naukowe
Tytuł :
Palmar Fasciitis and Polyarthritis Syndrome: A Rare Paraneoplastic Syndrome in a Patient With Prostate Carcinoma.
Autorzy :
de Boer AG; Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, Netherlands.
Klaasen R; Department of Rheumatology, Meander Medisch Centrum, Amersfoort, Netherlands.
van der Goes MC; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands.
Bloemendal HJ; Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, Netherlands.
Pokaż więcej
Źródło :
Journal of medical cases [J Med Cases] 2020 Sep; Vol. 11 (9), pp. 267-270. Date of Electronic Publication: 2020 Aug 06.
Typ publikacji :
Case Reports
Raport
Tytuł :
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective.
Autorzy :
de Joode K; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
Dumoulin DW; Department of Pulmonary Diseases, Erasmus MC, Rotterdam, the Netherlands.
Engelen V; Dutch Federation of Cancer Patient Organizations, Utrecht, the Netherlands.
Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Verheij M; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
van Laarhoven HWM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
Dingemans IH; Dutch Federation of Cancer Patient Organizations, Utrecht, the Netherlands.
Dingemans AC; Department of Pulmonary Diseases, Erasmus MC, Rotterdam, the Netherlands; Department of Pulmonary Diseases (GROW), School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
van der Veldt AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Sep; Vol. 136, pp. 132-139. Date of Electronic Publication: 2020 Jul 04.
Typ publikacji :
Journal Article
MeSH Terms :
Attitude to Health*
Telemedicine*
Time-to-Treatment*
Antineoplastic Agents/*therapeutic use
Coronavirus Infections/*epidemiology
Neoplasms/*therapy
Pneumonia, Viral/*epidemiology
Aged ; Betacoronavirus ; COVID-19 ; Female ; Humans ; Immunotherapy ; Incidence ; Male ; Medical Oncology ; Middle Aged ; Neoplasms/psychology ; Netherlands/epidemiology ; Pandemics ; Psycho-Oncology ; SARS-CoV-2 ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Pan-cancer whole-genome analyses of metastatic solid tumours.
Autorzy :
Priestley P; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Hartwig Medical Foundation Australia, Sydney, New South Wales, Australia.
Baber J; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Hartwig Medical Foundation Australia, Sydney, New South Wales, Australia.
Lolkema MP; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Steeghs N; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands.
de Bruijn E; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Shale C; Hartwig Medical Foundation Australia, Sydney, New South Wales, Australia.
Duyvesteyn K; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Haidari S; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
van Hoeck A; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.
Onstenk W; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Voda M; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Bloemendal HJ; Meander Medisch Centrum, Amersfoort, The Netherlands.; Radboud University Medical Center, Nijmegen, The Netherlands.
Tjan-Heijnen VCG; Maastricht University Medical Center, Maastricht, The Netherlands.
van Herpen CML; Radboud University Medical Center, Nijmegen, The Netherlands.
Labots M; VU Medical Center, Amsterdam, The Netherlands.
Witteveen PO; Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Smit EF; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands.
Sleijfer S; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Voest EE; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.; Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands.
Cuppen E; Hartwig Medical Foundation, Amsterdam, The Netherlands. .; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands. .; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands. .
Pokaż więcej
Źródło :
Nature [Nature] 2019 Nov; Vol. 575 (7781), pp. 210-216. Date of Electronic Publication: 2019 Oct 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation*
Precision Medicine*
Whole Genome Sequencing*
Neoplasm Metastasis/*genetics
Neoplasms/*genetics
Neoplasms/*pathology
Clone Cells/metabolism ; Clone Cells/pathology ; DNA Copy Number Variations ; Female ; Humans ; INDEL Mutation ; Information Dissemination ; Male
Czasopismo naukowe
Tytuł :
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Autorzy :
Ooft SN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Weeber F; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Dijkstra KK; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
McLean CM; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Kaing S; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
van Werkhoven E; Department of Biometrics, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Schipper L; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Hoes L; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Vis DJ; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Prevoo W; Department of Radiology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van der Velden D; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Klein M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Oncode Institute, 3521 AL Utrecht, Netherlands.
Chalabi M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Boot H; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
van Leerdam M; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, 6525 GA Nijmegen, Netherlands.
Beerepoot LV; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, 5042 AD Tilburg, Netherlands.
Wessels L; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, 2628 CD Delft, Netherlands.
Cuppen E; Oncode Institute, 3521 AL Utrecht, Netherlands.; Division Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, 3584 CX Utrecht, Netherlands.; Hartwig Medical Foundation, 1098 XH Amsterdam, Netherlands.
Clevers H; Oncode Institute, 3521 AL Utrecht, Netherlands.; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Centre Utrecht, 3584 CT Utrecht, Netherlands.; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands. .; Oncode Institute, 3521 AL Utrecht, Netherlands.; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
Pokaż więcej
Źródło :
Science translational medicine [Sci Transl Med] 2019 Oct 09; Vol. 11 (513).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Colorectal Neoplasms/*metabolism
Colorectal Neoplasms/*pathology
Organoids/*cytology
Antineoplastic Agents/therapeutic use ; Capecitabine/therapeutic use ; Colorectal Neoplasms/drug therapy ; Female ; Fluorouracil/therapeutic use ; Humans ; Irinotecan/therapeutic use ; Oxaliplatin/therapeutic use ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.
Autorzy :
Westgeest HM; Department of Internal Medicine, Amphia Ziekenhuis, Breda, The Netherlands. Electronic address: .
Kuppen MCP; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, The Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
de Wit R; Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Coenen JLLM; Department of Internal Medicine, Isala, Zwolle, The Netherlands.
van den Berg HPP; Department of Internal Medicine, Tergooi Ziekenhuizen, Hilversum, The Netherlands.
Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Fossion LMCL; Department of Urology, Maxima Medisch Centrum, Veldhoven, The Netherlands.
Hendriks MP; Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
Bloemendal HJ; Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, The Netherlands.
van de Luijtgaarden ACM; Department of Internal Medicine, Reinier de Graaf Gasthuis and Reinier Haga Prostate Cancer Centre, Delft, The Netherlands.
Ten Bokkel Huinink D; Department of Internal Medicine, Diakonessenhuis, Utrecht, The Netherlands.
van den Bergh ACMF; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
van den Bosch J; Department of Internal Medicine, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands.
Polee MB; Department of Internal Medicine, Medical Center, Leeuwarden, The Netherlands.
Weijl N; Department of Internal Medicine, MCH-Bronovo Ziekenhuis, 's-Gravenhage, The Netherlands.
Bergman AM; Division of Internal Medicine (MOD) and Oncogenomics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Uyl-de Groot CA; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, The Netherlands.
Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Clinical genitourinary cancer [Clin Genitourin Cancer] 2019 Oct; Vol. 17 (5), pp. e946-e956. Date of Electronic Publication: 2019 May 31.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Taxoids/*administration & dosage
Aged ; Antineoplastic Agents/adverse effects ; Clinical Trials as Topic ; Humans ; L-Lactate Dehydrogenase/metabolism ; Male ; Middle Aged ; Neoplasm Metastasis ; Netherlands ; Prognosis ; Prostate-Specific Antigen/metabolism ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Retrospective Studies ; Standard of Care ; Survival Analysis ; Taxoids/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.
Autorzy :
Angus L; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Smid M; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
van Riet J; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.; Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Van Hoeck A; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.
Nguyen L; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.
Nik-Zainal S; Department of Medical Genetics, The Clinical School, University of Cambridge, Cambridge, UK.
Steenbruggen TG; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
Tjan-Heijnen VCG; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Labots M; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
van Riel JMGH; Department of Internal Medicine, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
Bloemendal HJ; Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
Steeghs N; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
Voest EE; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
van de Werken HJG; Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Cuppen E; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
Martens JWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. .; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands. .
Pokaż więcej
Źródło :
Nature genetics [Nat Genet] 2019 Oct; Vol. 51 (10), pp. 1450-1458. Date of Electronic Publication: 2019 Sep 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation*
Biomarkers, Tumor/*genetics
Bone Neoplasms/*genetics
Breast Neoplasms/*genetics
Liver Neoplasms/*genetics
Lung Neoplasms/*genetics
Antineoplastic Agents/therapeutic use ; Bone Neoplasms/drug therapy ; Bone Neoplasms/secondary ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Cohort Studies ; Female ; Genomics ; Humans ; Liver Neoplasms/drug therapy ; Liver Neoplasms/secondary ; Lung Neoplasms/drug therapy ; Lung Neoplasms/secondary ; Prognosis
Czasopismo naukowe
Tytuł :
Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial.
Autorzy :
Schuurhuizen CSEW; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam.; Department of Psychiatry and Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam.
Braamse AMJ; Department of Medical Psychology, Cancer Center Amsterdam, Amsterdam Public Health Institute, Academic Medical Center, Amsterdam.
Beekman ATF; Department of Psychiatry and Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam.
Cuijpers P; Department of Clinical Psychology, VU University, Amsterdam.
van der Linden MHM; Department of Medical Psychology, and.
Hoogendoorn AW; Department of Psychiatry and Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam.
Berkhof H; Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam.
Sommeijer DW; Department of Medical Oncology, Flevoziekenhuis, Almere.
Lustig V; Department of Medical Oncology, Flevoziekenhuis, Almere.
Vrijaldenhoven S; Department of Medical Oncology, Noordwest Ziekenhuisgroep, Alkmaar.
Bloemendal HJ; Department of Medical Oncology, Meander Medical Center, Amersfoort.
van Groeningen CJ; Department of Medical Oncology, Hospital Amstelland, Amstelveen.
van Zweeden AA; Department of Medical Oncology, Hospital Amstelland, Amstelveen.
van der Vorst MJDL; Department of Medical Oncology, Rijnstate Hospital, Arnhem.
Rietbroek R; Department of Medical Oncology, Red Cross Hospital, Beverwijk.
Tromp-van Driel CS; Department of Medical Oncology, Noordwest Ziekenhuisgroep, Den Helder.
Wymenga MNW; Department of Medical Oncology, Medisch Spectrum Twente, Enschede.
van der Linden PW; Department of Medical Oncology, Spaarne Gasthuis, Haarlem.
Beeker A; Department of Medical Oncology, Spaarne Gasthuis, Hoofddorp.
Polee MB; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden.
Batman E; Department of Medical Oncology, Alrijne Hospital, Leiden.
Los M; Department of Medical Oncology, St. Antonius Hospital, Nieuwegein.
van Bochove A; Department of Medical Oncology, Zaans Medical Center, Zaandam; and.
Brakenhoff JAC; Department of Medical Oncology, Waterland Hospital, Purmerend, the Netherlands.
Konings IRHM; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam.
Verheul HMW; Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam.
Dekker J; Department of Psychiatry and Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam.
Pokaż więcej
Źródło :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2019 Aug 01; Vol. 17 (8), pp. 911-920.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Psychological Distress*
Stress, Psychological*
Colorectal Neoplasms/*complications
Trauma and Stressor Related Disorders/*etiology
Trauma and Stressor Related Disorders/*therapy
Aged ; Colorectal Neoplasms/epidemiology ; Colorectal Neoplasms/therapy ; Disease Management ; Female ; Humans ; Male ; Medical Futility ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Netherlands/epidemiology ; Quality of Life ; Randomized Controlled Trials as Topic ; Trauma and Stressor Related Disorders/diagnosis ; Trauma and Stressor Related Disorders/epidemiology
Czasopismo naukowe
Tytuł :
Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.
Autorzy :
Bouman-Wammes EW; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: .
de Klerk JMH; Department of Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands.
Bloemendal HJ; Department of Medical Oncology, UMC Utrech, Utrech, The Netherlands; Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.
Van Dodewaard-de Jong JM; Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.
Lange R; Department of Hospital Pharmacy, Meander Medical Center, Amersfoort, The Netherlands.
Ter Heine R; Department of Hospital Pharmacy, Radboud UMC, Nijmegen, The Netherlands.
Verheul HMW; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Van den Eertwegh AJM; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Clinical genitourinary cancer [Clin Genitourin Cancer] 2019 Apr; Vol. 17 (2), pp. e281-e292. Date of Electronic Publication: 2018 Nov 17.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bone Neoplasms/*drug therapy
Bone Neoplasms/*secondary
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Radiopharmaceuticals/*therapeutic use
Radium/*therapeutic use
Cancer Pain ; Clinical Trials as Topic ; Combined Modality Therapy ; Drug Therapy ; Humans ; Male ; Quality of Life ; Radioisotopes/therapeutic use ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Autorzy :
Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands; Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands. Electronic address: .
Uyl-de Groot CA; Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.
van Moorselaar RJA; Department of Urology, VU University Medical Center, Amsterdam, The Netherlands.
de Wit R; Department of Medical Oncology, ErasmusMC Cancer Institute, Rotterdam, The Netherlands.
van den Bergh ACM; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Coenen JLLM; Department of Internal Medicine, Isala, Zwolle, The Netherlands.
Beerlage HP; Department of Urology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands.
Hendriks MP; Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
Bos MMEM; Department of Internal Medicine, Reinier de Graaf Groep, Delft, The Netherlands.
van den Berg P; Department of Internal Medicine, Tergooi Ziekenhuizen, Hilversum, The Netherlands.
van de Wouw AJ; Department of Internal Medicine, Viecuri Medisch Centrum, Venlo, The Netherlands.
Spermon R; Department of Urology, Diakonessen Ziekenhuis, Utrecht, The Netherlands.
Boerma MO; Department of Urology, Deventer Ziekenhuis, Deventer, The Netherlands.
Geenen MM; Department of Internal Medicine, OLVG Locatie West, Amsterdam, The Netherlands.
Tick LW; Department of Internal Medicine, Maxima Medisch Centrum, Eindhoven, The Netherlands.
Polee MB; Department of Internal Medicine, Medical Center, Leeuwarden, The Netherlands.
Bloemendal HJ; Department of Internal Medicine/Oncology, Meander Medical Center, Amersfoort, The Netherlands.
Cordia I; Department of Urology, MCH-Bronovo Ziekenhuis, 's-Gravenhage, The Netherlands.
Peters FPJ; Department of Internal Medicine, Zuyderland Medisch Centrum, Heerlen-Sittard, The Netherlands.
de Vos AI; Department of Internal Medicine, van Weel Bethesda Ziekenhuis, Dirksland, The Netherlands.
van den Bosch J; Department of Internal Medicine, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
European urology focus [Eur Urol Focus] 2018 Sep; Vol. 4 (5), pp. 694-701. Date of Electronic Publication: 2016 Oct 13.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Pragmatic Clinical Trials as Topic/*methods
Prostatic Neoplasms/*drug therapy
Prostatic Neoplasms/*epidemiology
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Aged ; Aged, 80 and over ; Disease-Free Survival ; Docetaxel/administration & dosage ; Docetaxel/therapeutic use ; Humans ; Incidence ; Male ; Middle Aged ; Neoplasm Metastasis/pathology ; Netherlands/epidemiology ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/secondary ; Registries ; Retrospective Studies ; Treatment Outcome ; Tubulin Modulators/therapeutic use
Czasopismo naukowe
Tytuł :
Four-year effects of exercise on fatigue and physical activity in patients with cancer.
Autorzy :
Witlox L; Department of Clinical Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, STR 6.131, 3508 GA, Utrecht, The Netherlands.
Hiensch AE; Department of Clinical Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, STR 6.131, 3508 GA, Utrecht, The Netherlands.
Velthuis MJ; Netherlands Comprehensive Cancer Organisation (IKNL), PO Box 19079, 3501 DB, Utrecht, The Netherlands.
Steins Bisschop CN; Department of Clinical Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, STR 6.131, 3508 GA, Utrecht, The Netherlands.
Los M; Department of Medical Oncology, St. Antonius Ziekenhuis, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
Erdkamp FLG; Department of Internal Medicine - Medical Oncology, Obis Medisch Centrum, Dr van der Hoffplein 1, 6166 BG, Sittard-Geleen, The Netherlands.
Bloemendal HJ; Department of Internal Medicine, Meander Medical Center, Maatweg 3, 3818 TZ, Amersfoort, The Netherlands.
Verhaar M; Department of Internal Medicine, Hofpoort Ziekenhuis, Polanerbaan 2, 3447 GN, Woerden, The Netherlands.
Ten Bokkel Huinink D; Department of Internal Medicine, Diakonessenhuis, Bosboomstraat 1, 3582 KE, Utrecht, The Netherlands.
van der Wall E; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Peeters PHM; Department of Clinical Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, STR 6.131, 3508 GA, Utrecht, The Netherlands.
May AM; Department of Clinical Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, STR 6.131, 3508 GA, Utrecht, The Netherlands. .
Pokaż więcej
Źródło :
BMC medicine [BMC Med] 2018 Jun 08; Vol. 16 (1), pp. 86. Date of Electronic Publication: 2018 Jun 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Exercise/*physiology
Exercise Therapy/*methods
Fatigue/*rehabilitation
Neoplasms/*rehabilitation
Quality of Life/*psychology
Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies